Stereotactic Body Radiation and Stereotactic Ablative Radiotherapy Therapy for Cancers

<p><span style=color: rgba(23 43 77 1)>Within the last decade the radiation oncology community has witnessed increased adoption of hypo-fractionated high-precision radiation therapy using stereotactic body radiation therapy (SBRT) also referred to as stereotactic ablative radiotherapy (SABR) across many disease sites in the thorax abdomen and pelvis on the basis of clinical evidence demonstrating both efficacy and safety. The indication of SBRT/SABR is poised to greatly expand in coming years especially for the management of oligometastatic and oligoprogressive disease. Technological advancements in precision patient alignment in-room imaging tumor motion management and treatment machine deliveries have also expanded the feasibility of delivering ablative radiation doses while better sparing nearby critical organs thus markedly enhancing the therapeutic ratio.</span></p><p><span style=color: rgba(23 43 77 1)>Therefore this Special Issue aims to include articles on all types of stereotactic modalities and treatments (SBRT SABR and others) using ultra-hypofractionated and hypofractionated high-dose-per-fraction regimens including original research describing clinical outcomes and also describing novel treatment planning and delivery approaches.</span></p>